Pablo R. M.

Specialized interest lies in treating heart failure syndromes, including those driven by transthyretin amyloid cardiomyopathy and other infiltrative pathologies.

• Neurohormonal modulation in reduced‑ejection‑fraction heart failure
• Therapeutic approaches for amyloid‑related cardiac dysfunction
• Device‑based interventions for advanced heart failure
• Biomarker‑guided titration of guideline‑directed medical therapy

Research aims to improve functional outcomes and quality of life for patients with complex heart failure phenotypes.

The investigator addresses hereditary forms of cardiomyopathy, particularly dilated cardiomyopathy linked to pathogenic genetic variants.

• Screening of at‑risk family members
• Integration of genotype‑guided therapy
• Longitudinal monitoring of subclinical disease progression
• Collaboration with molecular diagnostics laboratories

Efforts are directed toward early identification and tailored interventions to mitigate disease onset.

Clinical investigations include conditions such as cancer‑associated thrombosis and arterial thromboembolic events.

• Risk assessment models for venous thromboembolism
• Anticoagulation management in oncologic patients
• Evaluation of novel antithrombotic agents
• Preventive strategies for arterial plaque instability

These activities support the development of safer, more effective antithrombotic regimens.

Advanced imaging modalities and circulating biomarkers are employed to refine diagnosis and prognostication.

• Echocardiographic assessment of ventricular function
• Cardiac magnetic resonance for tissue characterization
• Use of natriuretic peptides in therapeutic monitoring
• Integration of imaging data into clinical decision pathways

These tools enhance precision in patient selection for targeted cardiovascular therapies.